Novartis AG Registered Shares
NOVN: XSWX (CHE)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
CHF 73.00 | Vyc | Jcrmmtw |
Novartis Posts Slightly Weak Third Quarter, but Its Innovation Prospects Look Underappreciated
Novartis reported third-quarter results slightly below our projections, but we don’t expect any major changes to our fair value estimate. We continue to view the stock as undervalued, with the market not fully appreciating the growth of marketed drugs and pipeline treatments that also support the firm’s wide moat.